2022-11-10T13:56:39-06:00 2021-12-31 PricewaterhouseCoopers LLP 655 NEW YORK AVENUE NW STE 1100 WASHINGTON DC 20001 990 2021-01-01 473355381 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY % SARA COBLIN PARK 4159304386 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 MICHAEL POLANSKY EXEC. VP 4159304386 2022-11-10 true MICHAEL POLANSKY 999009999 TRAVIS PATTON P00369623 6464713000 3 2021 2022-09-23 18:48:47Z UTE DUGAN 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 170996190 false X WWW.PARKERICI.ORG X 2015 CA SEE SCHEDULE O 16 16 113 18 0 0 54173409 160955548 10178848 9757426 114246 94889 1560610 188327 66027113 170996190 26340166 9050381 0 0 18418734 20104846 51000 0 245997 25045856 23487994 69855756 52643221 -3828643 118352969 152630223 380437987 7859800 52905586 144770423 327532401 TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNOTHERAPIES TO TURN ALL CANCERS INTO CURABLE DISEASES BY SUPPORTING AND ACTIVELY ENGAGING IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS. false false 41567339 9050381 9757426 PICI ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI CONDUCTS ITS OWN RESEARCH AND CLINICAL TRIALS AND PROVIDES ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM. 41567339 true true false false false false false false false false true false true false true true true false false false true false false false false false false true false true false false false true false false false false true false false false true true false false false true 42 0 true 113 true false false false false false false false false false false false false X 16 16 true false false false false true true true true false false true true true true true true true true false CA X SARA COBLIN 4159857311 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 X UTE DUGAN MD CHIEF MEDICAL OFFICER 40.0 0.0 X 750812 0 40628 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 727762 0 10546 THERESA LAVALLE VP TRANSLATIONAL MEDICINE & RE 40.0 0.0 X 565786 0 44578 MELINDA GRIFFITH CHIEF LEGAL COUNSEL 40.0 0.0 X 520279 0 22561 RAMY IBRAHIM MD DIRECTOR & FORMER CMO 40.0 0.0 X 538067 0 1212 LISA BUTTERFIELD VP RESEARCH & DEVELOPMENT 40.0 0.0 X 428440 0 22746 JUSTIN FAIRCHILD VP CLINICAL DEVELOPMENT 40.0 0.0 X 401460 0 40628 FREDERIC PLA PHD COO THROUGH 4/15/21 40.0 0.0 X 377316 0 9009 MARKO SPASIC SENIOR MEDICAL DIRECTOR 40.0 0.0 X 363124 0 10787 SARA COBLIN SR VP FINANCE AS OF 6/1/21 40.0 0.0 X 284233 0 14469 SEAN N PARKER CHAIR OF THE BOARD & DIRECTOR 12.0 6.0 X X 0 0 0 MICHAEL POLANSKY EXECUTIVE VP & DIRECTOR 10.0 6.0 X X 0 0 0 TOM VAN LOBEN SELS TREASURER & DIRECTOR 1.0 0.0 X X 0 0 0 JEFFREY A BLUESTONE PHD VICE CHAIR & DIRECTOR 1.0 0.0 X 0 0 0 TONY COLES MD DIRECTOR 1.0 0.0 X 0 0 0 ERIC ESRAILIAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 SCOTT GOTTLIEB MD DIRECTOR 1.0 0.0 X 0 0 0 BEN HOROWITZ DIRECTOR 1.0 0.0 X 0 0 0 JEFF HUBER DIRECTOR 1.0 0.0 X 0 0 0 BOB HUGIN DIRECTOR 1.0 0.0 X 0 0 0 REED JOBS DIRECTOR 1.0 0.0 X 0 0 0 JOEL MARCUS DIRECTOR 1.0 0.0 X 0 0 0 BOB NELSEN DIRECTOR 1.0 0.0 X 0 0 0 BRUCE PARKER PHD DIRECTOR 1.0 0.0 X 0 0 0 BOB PITTMAN DIRECTOR 1.0 0.0 X 0 0 0 SUSAN DAWSON SECRETARY 10.0 5.0 X 0 0 0 4957279 0 217164 71 false true false ROSEWOOD MIRAMAR RESORT 1759 SOUTH JAMESON LANE MONTECITO CA 93108 CONFERENCE FACILITIE 1637706 XCANCER LLC 17607 GOLD PLAZA ACCOUNT RECEIVABLE OMAHA NE 68130 BIOBANKING & SAMPLE 1209238 ARIS CLINICAL INC 369B 3RD STREET 231 SAN RAFAEL CA 94901 CLINICAL TRIAL MONIT 686955 AZENTA-BROOKS LIFE SCIENCES FORTUNE CIRCLE WEST SUITE E INDIANAPOLIS IN 46241 BIOSTORAGE & SAMPLE 591720 SPENCER STUART PO BOX 98991 CHICAGO IL 60693 RECRUITING 594000 21 160955548 9865548 160955548 RESEARCH STUDY SPONSORSHIP 900099 9757426 9757426 9757426 94889 94889 0 188327 188327 0 0 0 0 0 0 0 0 0 0 0 0 0 0 170996190 9757426 283216 9050381 9050381 0 0 0 2754056 2069028 685028 0 14707068 9928769 4681512 96787 280078 210828 64075 5175 1374326 969471 392884 11971 989318 705564 277725 6029 0 2605522 2006373 599149 100400 100400 0 0 0 4109806 2454764 1584242 70800 172663 474 171837 352 289472 13861 273544 2067 2148761 1800730 348031 0 1342414 926266 402724 13424 326796 153620 162903 10273 0 2282213 2252421 29792 0 0 1646243 1646243 187419 187419 EXT R&D & OTHER CONTRACTS 7333249 7332459 0 790 RECRUITING 855715 0 855715 0 DUES & MEMBERSHIPS 87321 46087 12905 28329 52643221 41567339 10829885 245997 9358723 8333381 51722987 169344965 0 0 201165 1330218 140000 0 0 0 0 0 0 0 901494 828130 8706522 7015103 3652663 1691419 0 1000000 2500000 15500000 83826574 182409874 0 0 326617 0 152630223 380437987 7859800 7905586 0 0 0 0 0 0 0 0 0 7000000 0 0 0 0 0 38000000 7859800 52905586 X 110021679 318004204 34748744 9528197 144770423 327532401 152630223 380437987 X 118352969 64248034 626859 -1063556 597672 X false true X true false X MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK NY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER HOUSTON TX STANFORD MEDICINE STANFORD CA UNIVERSITY OF CALIFORNIA LOS ANGELES LOS ANGELES CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO CA UNIVERSITY OF PENNSYLVANIA PHILADELPHIA PA DANA-FARBER CANCER INSTITUTE BOSTON MA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK NY RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 720271 720271 0 7986251 6294833 1691419 1691419 IMAGIN-AB (EQUITY INVESTMENT) 1004281 F TMUNITY (EQUITY INVESTMENT) 30000000 F LYELL IMMUNOPHARMA,INC(EQUITY) 84645660 F ARSENAL BIOSCIENCES (EQUITY) 30334108 F ARSENAL BIOSCIENCES (CON NOTE) 13257000 F 3T BIOSCIENCES (EQUITY INVEST) 3104167 F PROJECT 5 (CONVERTIBLE NOTE) 10021370 F PSIOXUS (CONVERTIBLE NOTE) 10043288 F 182409874 0 CONDITIONAL CONTRIBUTIONS 38000000 38000000 X 234494893 64248034 626859 -1376190 63498703 170996190 170996190 51732915 51732915 910306 910306 52643221 PART X, LINE 2: PICI HAS NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES AS OF DECEMBER 31,2021 AND 2020 PART XI, LINE 2D - OTHER ADJUSTMENTS: PRIOR PERIOD ADJUSTMENT - (1,063,557) ADJUSTMENT FOR WRITE OFF OF LOC FOR ORIGINAL RENT - (302,633) OTHER ADJUSTMENT RELATED TO CONTRIBUTIONS RECEIVED - (10,000) PART XII, LINE 4B - OTHER ADJUSTMENTS GRANTS PAID ADJUSTMENT - 910,306 Europe (Including Iceland and Greenland) 0 0 Program Services RESEARCH SERVICES 401661 North America 0 0 Program Services SOFTWARE SERVICES 3795 Europe (Including Iceland and Greenland) 0 0 Investments 10043288 0 0 0 0 10448744 10448744 true false false false false false PART I, LINE 3: ACCRUAL BASIS true BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DURARTE RD DUARTE CA 91010 953432210 501(C)(3) 265883 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY CLINTON HEALTH ACCESS INITIATIVE INC 383 DORCHESTER AVENUE BOSTON MA 02127 271414646 501(C)(3) 380000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02115 042263040 501(C)(3) 1500000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY FHCRC - HUTCHINSON 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 325387 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY ICAHN SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 255346 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY INSTITUTE FOR SYSTEMS BIOLOGY 1801 LIND AVE SW RENTON WA 980579016 912003593 501(C)(3) 441957 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE BOX 69 NEW YORK NY 10065 912154267 501(C)(3) 797242 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF UNIVERSITY OF CALIFORNIA SAN FRANCISCO 333 CALIFORNIA ST 315 SAN FRANCISCO CA 94143 946036493 GOVT 574028 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 2768011 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 GOVT 572590 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 GOVT 137934 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF TEXAS MD ANDERSON 1400 PRESSLER STREET FCT295223 HOUSTON TX 77030 746001118 GOVT 250000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WASHINGTON UNIVERSITY 700 ROSEDALE AVENUE CB 1034 SAINT LOUIS MO 63112 430653611 501(C)(3) 250000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 36542 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WEILL CORNELL MEDICINE 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 495462 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 15 PART I, LINE 2: PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT APPLICABLE TO EACH INSTITUTION. X true true X X X false false false false false false false true true true RAMY IBRAHIM MD DIRECTOR & FORMER CMO 92464 0 192210 0 253393 0 0 0 1212 0 539279 0 0 0 UTE DUGAN MD CHIEF MEDICAL OFFICER 575000 0 172500 0 3312 0 8700 0 31928 0 791440 0 0 0 JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 558100 0 167430 0 2232 0 0 0 10546 0 738308 0 0 0 THERESA LAVALLE VP TRANSLATIONAL MEDICINE & RE 377353 0 37960 0 150473 0 8700 0 35878 0 610364 0 0 0 MELINDA GRIFFITH CHIEF LEGAL COUNSEL 392233 0 120000 0 8046 0 8700 0 13861 0 542840 0 0 0 LISA BUTTERFIELD VP RESEARCH & DEVELOPMENT 386300 0 38630 0 3510 0 8700 0 14046 0 451186 0 0 0 JUSTIN FAIRCHILD VP CLINICAL DEVELOPMENT 363102 0 36630 0 1728 0 8700 0 31928 0 442088 0 0 0 FREDERIC PLA PHD COO THROUGH 4/15/21 178150 0 132500 0 66666 0 1756 0 7253 0 386325 0 0 0 MARKO SPASIC SENIOR MEDICAL DIRECTOR 327894 0 34000 0 1230 0 0 0 10787 0 373911 0 0 0 SARA COBLIN SR VP FINANCE AS OF 6/1/21 213333 0 70000 0 900 0 4589 0 9880 0 298702 0 0 0 PART I, LINE 1A ANYONE TRAVELING OVER 3000 MILES CAN FLY BUSINESS CLASS OR FIRST CLASS (IF ONLY 2 LEVELS OF SERVICE ARE OFFERED). VP'S CAN TRAVEL BUSINESS OR FIRST CLASS FOR TRAVEL OVER 2000 MILES. PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER POSITION WAS VACANT DURING 2021. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES IN DETERMINING SUCH COMPENSATION: THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE REVIEWS ANY PROPOSED COMPENSATION, INCLUDING THE SALARY, OF ITS CHIEF EXECUTIVE OFFICER TO ENSURE THAT, IN EACH CASE, SUCH SALARY IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. PART I, LINE 7 MOST OF PICI'S EMPLOYMENT AGREEMENTS, WHICH ARE NEGOTIATED AT ARMS-LENGTH WITH REFERENCE TO COMPARABILITY DATA, CONTAIN A PROVISION PERMITTING ANNUAL INCENTIVE BONUSES, WHICH ARE CAPPED AT UP TO A FIXED PERCENTAGE. PART 1, LINE 8 THE ORGANIZATION ENTERED INTO A CONTRACT WITH SARA COBLIN EFFECTIVE 6/1/2021 THAT QUALIFIES FOR THE INITIAL CONTRACT EXCEPTION UNDER TREASURY REGULATION SECTION 53.4958-4(a)(3). THERESA LAVALLE EMPLOYEE RELOCATION X 250000 0 false true true RAMY IBRAHIM MD FORMER CMO & CONSULTANT/CURRENT DIRECTOR RELOCATION X 700000 0 false true true SEAN PARKER CHAIR OF THE BOARD & DIRECTOR OPERATING SUPPORT X 7000000 7000000 false true true 7000000 X 1 9865548 FMV false true false SCHEDULE M, PART I, COLUMN (B): THE NUMBERS REPORTED IN PART I, COLUMN (B) REPRESENT THE NUMBER OF CONTRIBUTIONS. FORM 990, PART 1, LINE 1 DESCRIPTION OF ORGANIZATION MISSION: THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) IS RADICALLY CHANGING THE WAY CANCER RESEARCH IS DONE. THE SAN FRANCISCO-BASED NONPROFIT IS AN UNPRECEDENTED COLLABORATION BETWEEN THE COUNTRY'S LEADING IMMUNOTHERAPY RESEARCHERS AND CANCER CENTERS, INCLUDING MEMORIAL SLOAN KETTERING CANCER CENTER, STANFORD MEDICINE, THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE UNIVERSITY OF PENNSYLVANIA AND THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER. THE INSTITUTE ALSO SUPPORTS TOP RESEARCHERS AT OTHER INSTITUTIONS, INCLUDING CITY OF HOPE, DANA-FARBER CANCER INSTITUTE, FRED HUTCHINSON CANCER RESEARCH CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, INSTITUTE FOR SYSTEMS BIOLOGY AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS. BY FORGING ALLIANCES WITH ACADEMIC, INDUSTRY AND NONPROFIT PARTNERS, PICI MAKES BIG BETS ON BOLD RESEARCH TO FULFILL ITS MISSION: TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TRANSFORM ALL CANCERS INTO CURABLE DISEASES. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS IS COMPRISED OF ONE 'CLASS A' DIRECTOR WITH THE BALANCE OF THE DIRECTORS SERVING AS 'CLASS B' DIRECTORS. THE CLASS A DIRECTOR MUST BE PRESENT TO CONSTITUTE A QUORUM, UNLESS THE CLASS A DIRECTOR'S RECUSAL IS REQUIRED BY LAW OR CORPORATE POLICY. EACH DIRECTOR IS ENTITLED TO ONE VOTE. ANY ACT OF THE BOARD OF DIRECTORS REQUIRES THE AFFIRMATIVE VOTE OF BOTH THE CLASS A DIRECTOR AND A MAJORITY OF THE CLASS B DIRECTORS PRESENT AT A MEETING AT WHICH A QUORUM IS PRESENT, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS. PICI DOES HAVE AN EXECUTIVE COMMITTEE. IT HAS ALL THE AUTHORITY OF THE BOARD OF DIRECTORS BETWEEN REGULAR AND SPECIAL MEETINGS, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS OR BY THE BOARD OF DIRECTORS IN SPECIFIC INSTANCES. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO AND REVIEWED BY THE BOARD OF DIRECTORS AT ITS NEXT REGULARLY SCHEDULED MEETING. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS HAVE A BUSINESS RELATIONSHIP: JEFFREY BLUESTONE, JOHN CONNOLLY, SUSAN DAWSON, ERIC ESRAILIAN, BEN HOROWITZ, JEFF HUBER, REED JOBS, BOB NELSEN, BRUCE PARKER, SEAN PARKER, BOB PITTMAN, MICHAEL POLANSKY, AND TOM VAN LOBEN SELS. THE FOLLOWING DIRECTORS HAVE A FAMILY RELATIONSHIP: SEAN PARKER AND BRUCE PARKER. FORM 990, PART VI, SECTION A, LINE 7A THE DESIGNATOR HAS THE AUTHORITY TO APPOINT MEMBERS OF PICI'S GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 7B THE DESIGNATOR HAS THE AUTHORITY TO REMOVE MEMBERS OF PICI'S GOVERNING BODY, TO CONSENT TO SUCH REMOVAL BY THE BOARD, AND TO CONSENT TO ANY AMENDMENTS TO PICI'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD AUTHORIZES AND OVERSEES A REVIEW OF THE ADMINISTRATION OF THE CONFLICT OF INTEREST POLICY. THE REVIEW CONSIDERS THE LEVEL OF COMPLIANCE WITH THE POLICY, THE CONTINUING SUITABILITY OF THE POLICY, AND WHETHER THE POLICY SHOULD BE MODIFIED AND IMPROVED. IF A TRANSACTION ARISES WHERE THERE IS A CONFLICT OF INTEREST, THE PERSON WITH SUCH CONFLICT IS NOT ALLOWED TO VOTE ON THE TRANSACTION NOR BE PRESENT FOR SUCH VOTE. THE CONFLICT OF INTEREST POLICY COVERS EACH DIRECTOR, CORPORATE OFFICER, TOP MANAGEMENT OFFICIAL, TOP FINANCIAL OFFICIAL AND EACH KEY EMPLOYEE OF PICI, AND OTHERS THAT PICI MAY IDENTIFY. FORM 990, PART VI, SECTION B, LINE 15 FORM 990, PART VI, SECTION B, LINE 15A - AS STATED AT SCHEDULE J, PART I, LINE 3, THE CEO POSITION WAS VACANT DURING THE 2021 CALENDAR YEAR. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES: THE BOARD OF DIRECTORS APPROVES THE SALARY OF PICI'S CHIEF EXECUTIVE OFFICER ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 15B IN GENERAL, PICI WORKED WITH A RECRUITER AND, AS PART OF THAT PROCESS, ROUTINELY COMPARED THE PROPOSED SALARY WITH SALARIES PAID BY OTHER ORGANIZATIONS FOR SIMILAR POSITIONS. FORM 990, PART VI, SECTION C, LINE 19 PICI'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AS REQUIRED BY LAW. FORM 990, PART XI, LINE 9 GRANTS PAID ADJUSTMENT - 910,305 ADJUSTMENT FOR WRITE OFF OF LOC FOR ORIGINAL RENT - (302,633) OTHER ADJUSTMENT RELATED TO CONTRIBUTIONS RECEIVED - (10,000) FORM 990, PART VII, SECTION A, LINE 1A RAMY IBRAHIM'S COMPENSATION RELATES TO HIS POSITION AS AN EMPLOYEE THROUGH JANUARY 1, 2021 AND RECEIVED LOAN FORGIVENESS AND CONSULTING COMPENSATION POST-TERMINATION AND NOT AS A TRUSTEE/DIRECTOR. MAVERIC LLC 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 853467441 COVID-19 CLIN CA 0 0 PICI SEAN N PARKER FOUNDATION 314 LYTTON AVE PALTO ALTO CA 94301 274389819 NONPROFIT SUP CA 501(C)(3) PF NA false ECONOMIC INNOVATION GROUP INC 616 H STREET NW SUITE 550 WASHINGTON DC 20001 462450336 PUBLIC INTERE DC 501(C)(4) N/A NA false false false false false true false false false false false false false false false false false false false false PART I, IDENTIFICATION OF DISREGARDED ENTITIES: NAME, ADDRESS, AND EIN OF DISREGARDED ENTITY: MAVERIC, LLC EIN: 85-3467441 1 LETTERMAN DRIVE, D3500 SAN FRANCISCO, CA 94129 PRIMARY ACTIVITY: COVID-19 CLINICAL TRIAL MANAGEMENT (CURRENTLY INACTIVE) DIRECT CONTROLLING ENTITY: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY SCHEDULE R, SUPPLEMENTAL INFORMATION: THE CLASS A DIRECTOR ALSO HAS A CONTROLLING INTEREST IN SEVERAL PASSIVE INVESTMENT VEHICLES. THESE INVESTMENT VEHICLES AND THE TAX-EXEMPT ENTITIES DISCLOSED UNDER PART II ABOVE MAY TECHNICALLY BE CONSIDERED "RELATED ORGANIZATIONS" OF PICI FOR IRS FORM 990 REPORTING PURPOSES THROUGH THEIR RELATIONSHIP WITH THE CLASS A DIRECTOR. THE PASSIVE INVESTMENT VEHICLES HAVE NO TRANSACTIONS OR BUSINESS RELATIONSHIPS WITH PICI AND ARE NOT DISCLOSED ON SCHEDULE R.